We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pan-European Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00542867
Recruitment Status : Completed
First Posted : October 12, 2007
Last Update Posted : November 20, 2007
Sponsor:
Information provided by:

Study Description
Brief Summary:
The survey try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.·

Condition or disease
Hypercholesterolemia

Study Design

Study Type : Observational
Actual Enrollment : 6500 participants
Time Perspective: Prospective
Official Title: Pan-European Survey on the Under Treatment of Hypercholesterolemia
Study Start Date : January 2006
Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. The number and percentage of patients achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and by country.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00542867


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: M. Hermans UCL
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00542867     History of Changes
Other Study ID Numbers: SRP-CB-CRE-2006/01
First Posted: October 12, 2007    Key Record Dates
Last Update Posted: November 20, 2007
Last Verified: November 2007

Keywords provided by AstraZeneca:
Hypercholesterolemia
Third Joint European Task Force guidelines
Survey

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases